CDC Offers New Advice for Managing Shigella Infection Given Reduced Antibiotic Susceptibility — Physician’s First Watch

Medical News |
April 20, 2017

CDC Offers New Advice for Managing Shigella Infection Given Reduced Antibiotic Susceptibility

By Kelly Young

Edited by Richard Saitz, MD, MPH, FACP, DFASAM

The CDC is emphasizing that clinicians not treat Shigella infection with antibiotics unless it is clinically indicated — for example, in patients who are immunocompromised or who have severe illness — or during an outbreak. The agency's health advisory comes amid growing fluoroquinolone resistance in Shigella samples.

In suspected cases of shigellosis, clinicians should order stool culture and antimicrobial susceptibility testing. If antibiotics are indicated but the ciprofloxacin minimum inhibitory concentration is 0.12 µg/mL or higher, fluoroquinolones should be avoided and clinicians should consult their clinical microbiology laboratory and an infectious disease specialist to decide on an appropriate antibiotic. For patients with continued or worsening symptoms after antibiotic therapy, follow-up stool culture should be obtained.

The CDC is investigating whether ciprofloxacin treatment could increase illness duration or symptom severity in patients with Shigella harboring a quinolone-resistance gene.

Reader Comments (1)

michael posner Physician, Pediatrics/Adolescent Medicine

this the way it went for salmonella back in the 80s, when it was found that salmonella carriage was more persistent after antibiotic use. shigella took a while longer to have the guidelines for treatment changed.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.